Nevertheless, the tpCR rates of the P + EC-TH neoadjuvant regimen in our study and Xuhong's study were about twice as high as that of the EC-TH neoadjuvant regimen reported in other trials, suggesting that patients with HER2-positive breast cancer treated with EC-TH neoadjuvant regimen can use pyrotinib simultaneously, obtaining a higher tpCR rate and better prognosis. This evidence concerns the gene ERBB2 and breast cancer.